Author Archives: Gastroenterology Journal
MINORITY IBS PATIENTS RECEIVE MORE GI-RELATED PROCEDURES THAN WHITE COUNTERPARTS: NUANCES IN DISPARITIES RESEARCH
Esophageal stricture: Not your usual culprit?
Endoscopic surveillance in IBD: The VIRTUE is in high definition.
MIRROR MIRROR ON THE WALL, WHO IS THE FITTEST OF THEM ALL: A NOVEL PREDICTION MODEL FOR POSTOPERATIVE HEPATIC DECOMPENSATION IN PATIENTS WITH CIRRHOSIS
Patients with cirrhosis carry an increased risk for mortality and morbidity after surgery (Ann Surg 2021;274:e345-54). Assessing the surgical risks for these patients has been a challenging issue for providers, given the complicated pathophysiology and… Continue reading
HLA Class I analysis provides insight into the genetic and epigenetic background of immune evasion in colorectal cancer with high microsatellite instability.
A detailed understanding of antitumor immunity is essential for optimal cancer immune therapy. Although defective mutations in the B2M and HLA-ABC genes, which encode molecules essential for antigen presentation, have been reported in several studies, … Continue reading
Prolonged impairment of short-chain fatty acid and L-isoleucine biosynthesis in gut microbiome in patients with COVID-19
SARS-CoV-2 infection is associated with altered gut microbiota composition. Phylogenetic groups of gut bacteria involved in the metabolism of short chain fatty acids were depleted in SARS-CoV-2-infected patients. We aimed to characterize functional pro… Continue reading
Loss of Endothelial TSPAN12 Promotes Fibrostenotic Eosinophilic Esophagitis via Endothelial Cell–Fibroblast Crosstalk
Eosinophilic esophagitis (EoE) can progress to fibrostenosis by unclear mechanisms. Herein, we investigated gene dysregulation in fibrostenotic EoE, its association with clinical parameters and specific pathways, and the functional consequences. Continue reading
Comparing colorectal cancer screening outcomes in the International Cancer Screening Network (ICSN): A Consortium proposal
Connecting the dots: Dietary fat, microbiota dysbiosis, altered metabolome and colon cancer
Burden and Cost of Gastrointestinal, Liver, and Pancreatic Diseases in the United States: Update 2021
Gastrointestinal diseases account for considerable health care use and expenditures. We estimated the annual burden, costs, and research funding associated with gastrointestinal, liver, and pancreatic diseases in the United States. Continue reading